Next-generation sequencing to guide cancer therapy

Table 2 FDA-approved drugs with a companion diagnostic

Drug	Disease	DNA mutation	Action
Imatinib, Dasatinib, Nilotinib, Bosutinib	Chronic myelogenous leukemia	BCR-ABL1 fusion	Indication for therapy
Ponatinib	Chronic myelogenous leukemia	BCR-ABL1 fusion	Only indicated for T315I mutations
Ponatinib	Chronic myelogenous leukemia	T315I resistance mutation	Only indicated for T315I mutations
Erlotinib, Afatinib	Lung adenocarcinoma	EGFR	Indication for therapy
		Exon 19 deletions
		L858R
Vemurafenib, Dabrafenib	Melanoma	BRAF V600E	Indication for therapy
Tramatenib	Melanoma	BRAF V600E/K	Indication for therapy
Crizotinib	Lung cancer	ALK gene fusions	Indication for therapy
Cetuximab	Colon cancer	KRAS codon 12, 13	Contraindication to therapy
Olaparib	Ovarian cancer	BRCA1 and BRCA2 mutations	Indication for therapy

Each drug has a specific genomic result that is part of its indication for use. FDA Food and Drug Administration